Sienna Cancer Diagnostics Ltd. named Helen Fisher an independent nonexecutive director, effective March 28.

Fisher will also act as chair of the company's audit and risk committee. She was a partner at Deloitte and adviser to several life sciences and biotechnology companies, Sienna Cancer Diagnostics said in a news release.

Australia-based Sienna Cancer is a medical technology company developing and marketing innovative cancer related tests, with operations in the U.S. and Europe.